SCHEMBL5543785

SCHEMBL5543785

[CH2]c1ccccc1NCc1ccccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.50
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 1/20 0.49
MAPT P10636 3/20 0.46
ATM Q13315 1/20 0.46
PLA2G1B P04054 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
ATG4B Q9Y4P1 1/20 0.46
LMNA P02545 4/20 0.46
KDM4E B2RXH2 2/20 0.44
CA12 O43570 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
MPO P05164 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544340 0.88 L3MBTL1 (0.46) L3MBTL1KMT2AMEN1CYP1A2CYP2C9
SCHEMBL5542378 0.83 MAOB (0.42) L3MBTL1KDM4EGAA
SCHEMBL5540496 0.81 HTT (0.39) L3MBTL1KMT2AMEN1ALDH1A1MAPT
SCHEMBL5537895 0.80 KDM1A (0.46) L3MBTL1KMT2AMEN1CYP1A2CYP2C9
SCHEMBL28860071 0.79 L3MBTL1 (0.51) L3MBTL1KMT2AMEN1CYP1A2CYP2C9
SCHEMBL688010 0.78 MAPT (0.53) KMT2AMEN1CYP1A2CYP2C9CYP2C19
SCHEMBL5539677 0.78 CA12 (0.44) L3MBTL1KMT2AMEN1ALDH1A1HPGD
SCHEMBL5536067 0.78 CA12 (0.44) L3MBTL1KMT2AMEN1CYP1A2CYP2C9
SCHEMBL5536341 0.77 KDM4E (0.45) L3MBTL1ALDH1A1ATMCYP3A4KDM4E
SCHEMBL5535837 0.76 CA12 (0.33) L3MBTL1KMT2AMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 L3MBTL1 1931/4885KMT2A 4267/4885MEN1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.